Objective The RetinArt project addresses a major public health issue: cardiovascular (CV) events, which are the leading cause of death in the world. The overall project objective is to validate the arteriolar wall-to-lumen ratio (AWLR), a clinical biomarker of the alterations caused by arterial hypertension (AHT) in small arteries. The clinical validation is expected to prove that assessments of the AWLR enable earlier detection of damage caused by AHT, better prediction of CV risk, and more effective adaptation of AHT therapy to patient.To measure the AWLR biomarker, Imagine Eyes has developed a new retinal imaging system that uses the eye as a window to the microcirculatory system. This instrumentation provides unparalleled microscopic resolution thanks to a breakthrough adaptive optics technology derived from astrophysics. It enables clinicians, for the first time, to directly visualize the microscopic walls of retinal arterioles and quantify the AWLR using automated segmentation software. The examination procedure is totally non invasive and its reliability has been successfully tested with AHT patients in a hospital environment.The phase 1 of the RetinArt project is a feasibility study that aims at establishing the methodological and economic validity of the proposed clinical validation, and at planning its future execution. The main deliverables expected from phase 1 are a validation plan and a detailed business plan. These outcomes are essential milestones in the translation of Imagine Eyes technology to a new standard that will help reduce the risk of serious complications in wide numbers of AHT patients. Fields of science medical and health scienceshealth sciencespublic healthmedical and health sciencesclinical medicineophthalmologynatural sciencesphysical sciencesastronomyastrophysicsmedical and health sciencesclinical medicinecardiologycardiovascular diseasesmedical and health sciencesbasic medicineneurology Programme(s) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.3. - Treating and managing disease Topic(s) PHC-12-2014-1 - Clinical research for the validation of biomarkers and/or diagnostic medical devices Call for proposal H2020-SMEInst-2014-2015 See other projects for this call Sub call H2020-SMEINST-1-2014 Funding Scheme SME-1 - SME instrument phase 1 Coordinator IMAGINE EYES SA Net EU contribution € 50 000,00 Address RUE CHARLES DE GAULLE 18 91400 ORSAY France See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Ile-de-France Ile-de-France Essonne Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 71 429,00